The PD-1/PD-L1 pathway as an immunotherapy target against cancer

Abstract: The PD-1/PD-L1 pathway attenuates tissue destruction by limiting the activity of T cells, a situation that can be used by cancer to its advantage. Thus, blocking the PD-1/PD-L1 pathway provides a basis for immunotherapy against cancer, which is very promising when considering the high inci...

Descripción completa

Detalles Bibliográficos
Autores: Arce Araya, Angélica, Hernández García, Carolina, Neily Younes, Paula, Mata Jinesta, Valeria, Serrano Silva, María Belén, Ulate Sancho, Carolina, Reyes Moreno, Ledis
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:Costa Rica
Institución:Universidad de Costa Rica
Repositorio:Portal de Revistas UCR
Idioma:español
OAI Identifier:oai:portal.ucr.ac.cr:article/48625
Acceso en línea:https://revistas.ucr.ac.cr/index.php/medica/article/view/48625
Access Level:acceso abierto
id CR_b514b8a4404ede8170747d84c99b4950
oai_identifier_str oai:portal.ucr.ac.cr:article/48625
network_acronym_str CR
network_name_str Costa Rica
repository_id_str
dc.title.none.fl_str_mv The PD-1/PD-L1 pathway as an immunotherapy target against cancer
La Vía de PD-1/PD-L1 como blanco de inmunoterapia contra el Cáncer
title The PD-1/PD-L1 pathway as an immunotherapy target against cancer
spellingShingle The PD-1/PD-L1 pathway as an immunotherapy target against cancer
Arce Araya, Angélica
title_short The PD-1/PD-L1 pathway as an immunotherapy target against cancer
title_full The PD-1/PD-L1 pathway as an immunotherapy target against cancer
title_fullStr The PD-1/PD-L1 pathway as an immunotherapy target against cancer
title_full_unstemmed The PD-1/PD-L1 pathway as an immunotherapy target against cancer
title_sort The PD-1/PD-L1 pathway as an immunotherapy target against cancer
dc.creator.none.fl_str_mv Arce Araya, Angélica
Hernández García, Carolina
Neily Younes, Paula
Mata Jinesta, Valeria
Serrano Silva, María Belén
Ulate Sancho, Carolina
Reyes Moreno, Ledis
author Arce Araya, Angélica
author_facet Arce Araya, Angélica
Hernández García, Carolina
Neily Younes, Paula
Mata Jinesta, Valeria
Serrano Silva, María Belén
Ulate Sancho, Carolina
Reyes Moreno, Ledis
author_role author
author2 Hernández García, Carolina
Neily Younes, Paula
Mata Jinesta, Valeria
Serrano Silva, María Belén
Ulate Sancho, Carolina
Reyes Moreno, Ledis
author2_role author
author
author
author
author
author
description Abstract: The PD-1/PD-L1 pathway attenuates tissue destruction by limiting the activity of T cells, a situation that can be used by cancer to its advantage. Thus, blocking the PD-1/PD-L1 pathway provides a basis for immunotherapy against cancer, which is very promising when considering the high incidence and mortality rates that this disease currently presents. Therefore, this research consists of a descriptive bibliographic review that was performed using the database of the System of Libraries, Documentation, and Information of the University of Costa Rica (SIBDI in Spanish) and the website Google Scholar. The objective of this review is to determine the role of the PD-1/PD-L1 pathway as an immune checkpoint, in addition to the application of the PD-1 and PD-L1 inhibitor drugs in immunotherapy against cancer. It was concluded that PD-1/PD-L1 inhibitors have high rates of antitumor response and survival, as well as better tolerance than traditional antitumor drugs. Finally, combination therapy and the use of biomarkers are recommended to obtain a higher tumor progression-free survival, a personalized therapy and a favorable outcome for the patient.
publishDate 2021
dc.date.none.fl_str_mv 2021-10-24
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
artículo original
http://purl.org/coar/resource_type/c_2df8fbb1
info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://revistas.ucr.ac.cr/index.php/medica/article/view/48625
10.15517/rmucr.v15i2.48625
url https://revistas.ucr.ac.cr/index.php/medica/article/view/48625
identifier_str_mv 10.15517/rmucr.v15i2.48625
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://revistas.ucr.ac.cr/index.php/medica/article/view/48625/48375
https://revistas.ucr.ac.cr/index.php/medica/article/view/48625/48493
https://revistas.ucr.ac.cr/index.php/medica/article/view/48625/48495
dc.rights.none.fl_str_mv Derechos de autor 2021 ©
acceso abierto
http://purl.org/coar/access_right/c_abf2
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2021 ©
acceso abierto
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
text/xml
audio/mpeg
dc.publisher.none.fl_str_mv Universidad de Costa Rica
publisher.none.fl_str_mv Universidad de Costa Rica
dc.source.none.fl_str_mv Revista Médica de la Universidad de Costa Rica; Vol. 15 No. 2 (2021): Medical Journal of the University of Costa Rica Volume 15, Number 2 October 2021-April 2022; 61-81
Revista Médica de la Universidad de Costa Rica; Vol. 15 Núm. 2 (2021): Revista Medica de la Universidad de Costa Rica Volumen 15, Número 2 Octubre 2021-Abril de 2022; 61-81
1659-2441
reponame:Portal de Revistas UCR
instname:Universidad de Costa Rica
instacron:UCR
instname_str Universidad de Costa Rica
instacron_str UCR
institution UCR
reponame_str Portal de Revistas UCR
collection Portal de Revistas UCR
repository.name.fl_str_mv Portal de Revistas UCR - Universidad de Costa Rica
repository.mail.fl_str_mv jorge.polanco@ucr.ac.cr
_version_ 1849325458999476224
spelling The PD-1/PD-L1 pathway as an immunotherapy target against cancerLa Vía de PD-1/PD-L1 como blanco de inmunoterapia contra el CáncerArce Araya, AngélicaHernández García, CarolinaNeily Younes, PaulaMata Jinesta, ValeriaSerrano Silva, María BelénUlate Sancho, CarolinaReyes Moreno, LedisAbstract: The PD-1/PD-L1 pathway attenuates tissue destruction by limiting the activity of T cells, a situation that can be used by cancer to its advantage. Thus, blocking the PD-1/PD-L1 pathway provides a basis for immunotherapy against cancer, which is very promising when considering the high incidence and mortality rates that this disease currently presents. Therefore, this research consists of a descriptive bibliographic review that was performed using the database of the System of Libraries, Documentation, and Information of the University of Costa Rica (SIBDI in Spanish) and the website Google Scholar. The objective of this review is to determine the role of the PD-1/PD-L1 pathway as an immune checkpoint, in addition to the application of the PD-1 and PD-L1 inhibitor drugs in immunotherapy against cancer. It was concluded that PD-1/PD-L1 inhibitors have high rates of antitumor response and survival, as well as better tolerance than traditional antitumor drugs. Finally, combination therapy and the use of biomarkers are recommended to obtain a higher tumor progression-free survival, a personalized therapy and a favorable outcome for the patient.Resumen: La vía de PD-1/PD-L1 atenúa la destrucción de tejidos al limitar la actividad de las células T, situación que el cáncer puede utilizar a su favor. El bloqueo de la vía PD-1/PD-L1 proporciona entonces, una base para la inmunoterapia contra el cáncer, lo cual resulta muy prometedor al considerar las altas tasas de incidencia y mortalidad que presenta dicha enfermedad en la actualidad. La presente investigación consiste en una revisión bibliográfica descriptiva realizada mediante la consulta de la base de datos Sistema de Bibliotecas, Documentación e Información (SIBDI) de la Universidad de Costa Rica y el sitio web Google Scholar (Google Académico). El objetivo de esta revisión es determinar la función de la vía de PD-1/PD-L1 como punto de control inmunológico, junto con la aplicación y el alcance de los fármacos inhibidores de PD-1 y PD-L1 en la inmunoterapia contra el cáncer. Se concluye que los inhibidores de PD-1/PD-L1 presentan altas tasas de respuesta antitumoral y supervivencia, así como una mejor tolerancia en comparación a fármacos antitumorales tradicionales.  Finalmente, se recomienda la terapia combinada y el uso de biomarcadores para obtener una mayor supervivencia libre de progresión tumoral, una terapia personalizada y un resultado favorable para el paciente.Universidad de Costa Rica2021-10-24info:eu-repo/semantics/publishedVersionartículo originalhttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleapplication/pdftext/xmlaudio/mpeghttps://revistas.ucr.ac.cr/index.php/medica/article/view/4862510.15517/rmucr.v15i2.48625Revista Médica de la Universidad de Costa Rica; Vol. 15 No. 2 (2021): Medical Journal of the University of Costa Rica Volume 15, Number 2 October 2021-April 2022; 61-81Revista Médica de la Universidad de Costa Rica; Vol. 15 Núm. 2 (2021): Revista Medica de la Universidad de Costa Rica Volumen 15, Número 2 Octubre 2021-Abril de 2022; 61-811659-2441reponame:Portal de Revistas UCRinstname:Universidad de Costa Ricainstacron:UCRspahttps://revistas.ucr.ac.cr/index.php/medica/article/view/48625/48375https://revistas.ucr.ac.cr/index.php/medica/article/view/48625/48493https://revistas.ucr.ac.cr/index.php/medica/article/view/48625/48495Derechos de autor 2021 ©acceso abiertohttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccess2022-03-01T19:48:40Zoai:portal.ucr.ac.cr:article/48625Portal de revistashttps://revistas.ucr.ac.cr/Universidadhttp://www.ucr.ac.crhttps://revistas.ucr.ac.cr/index.php/index/oaijorge.polanco@ucr.ac.crCosta RicaNo aplicaNo aplicaNo aplicaopendoar:2025-08-13T10:50:27.080Portal de Revistas UCR - Universidad de Costa Ricafalse
score 15.811543

Similares en LA Referencia